These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Janocko NJ; Brodersen KA; Soto-Ortolaza AI; Ross OA; Liesinger AM; Duara R; Graff-Radford NR; Dickson DW; Murray ME Acta Neuropathol; 2012 Nov; 124(5):681-92. PubMed ID: 22968369 [TBL] [Abstract][Full Text] [Related]
5. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Armstrong RA Folia Neuropathol; 2009; 47(4):289-99. PubMed ID: 20054780 [TBL] [Abstract][Full Text] [Related]
6. Tauopathy: A common mechanism for neurodegeneration and brain aging. Saha P; Sen N Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956 [TBL] [Abstract][Full Text] [Related]
13. Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals. Schultz N; Byman E; ; Wennström M J Alzheimers Dis; 2020; 73(3):1201-1209. PubMed ID: 31884473 [TBL] [Abstract][Full Text] [Related]
14. Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease. Saroja SR; Sharma A; Hof PR; Pereira AC Alzheimers Dement; 2022 Sep; 18(9):1602-1615. PubMed ID: 34873815 [TBL] [Abstract][Full Text] [Related]
15. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo. DeVos SL; Corjuc BT; Commins C; Dujardin S; Bannon RN; Corjuc D; Moore BD; Bennett RE; Jorfi M; Gonzales JA; Dooley PM; Roe AD; Pitstick R; Irimia D; Frosch MP; Carlson GA; Hyman BT Brain; 2018 Jul; 141(7):2194-2212. PubMed ID: 29733334 [TBL] [Abstract][Full Text] [Related]
16. Extracranial carotid atherosclerosis is associated with increased neurofibrillary tangle accumulation. Arias JC; Edwards M; Vitali F; Beach TG; Serrano GE; Weinkauf CC J Vasc Surg; 2022 Jan; 75(1):223-228. PubMed ID: 34478810 [TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Díaz-Nido J; Wandosell F; Avila J Peptides; 2002 Jul; 23(7):1323-32. PubMed ID: 12128089 [TBL] [Abstract][Full Text] [Related]
18. Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease. Chung J; Zhang X; Allen M; Wang X; Ma Y; Beecham G; Montine TJ; Younkin SG; Dickson DW; Golde TE; Price ND; Ertekin-Taner N; Lunetta KL; Mez J; ; Mayeux R; Haines JL; Pericak-Vance MA; Schellenberg G; Jun GR; Farrer LA Alzheimers Res Ther; 2018 Feb; 10(1):22. PubMed ID: 29458411 [TBL] [Abstract][Full Text] [Related]
19. Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid β. Uematsu M; Nakamura A; Ebashi M; Hirokawa K; Takahashi R; Uchihara T Acta Neuropathol Commun; 2018 Jan; 6(1):1. PubMed ID: 29298724 [TBL] [Abstract][Full Text] [Related]
20. Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer's disease pathogenesis: Potential strategies to protect the LC against aging. Satoh A; Iijima KM Brain Res; 2019 Jan; 1702():17-28. PubMed ID: 29274876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]